Somewhat Positive Press Coverage Somewhat Unlikely to Affect LeMaitre Vascular (LMAT) Stock Price

Media coverage about LeMaitre Vascular (NASDAQ:LMAT) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. LeMaitre Vascular earned a news impact score of 0.03 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 46.2935528754585 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of LeMaitre Vascular (NASDAQ LMAT) opened at $34.28 on Wednesday. The stock has a market capitalization of $656.93, a P/E ratio of 44.29, a P/E/G ratio of 2.71 and a beta of 0.55. LeMaitre Vascular has a 12 month low of $19.82 and a 12 month high of $39.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The business had revenue of $24.80 million during the quarter, compared to analysts’ expectations of $25.49 million. During the same period in the previous year, the company posted $0.17 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. equities analysts expect that LeMaitre Vascular will post 0.84 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 7th. Shareholders of record on Wednesday, November 22nd will be paid a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Tuesday, November 21st. LeMaitre Vascular’s payout ratio is presently 28.57%.

LeMaitre Vascular announced that its board has authorized a stock repurchase program on Thursday, July 27th that allows the company to buyback $7.50 million in shares. This buyback authorization allows the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Stifel Nicolaus reissued a “buy” rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Canaccord Genuity lowered their price target on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating on the stock in a research report on Friday, October 27th. Benchmark Co. downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Finally, First Analysis downgraded LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price target on the stock. in a research report on Friday, October 27th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. LeMaitre Vascular currently has an average rating of “Hold” and an average price target of $32.20.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect LeMaitre Vascular (LMAT) Stock Price” was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://weekherald.com/2017/11/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-lemaitre-vascular-lmat-share-price.html.

In other news, CEO George W. Lemaitre sold 5,000 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $33.91, for a total value of $169,550.00. Following the completion of the transaction, the chief executive officer now directly owns 3,390,508 shares in the company, valued at approximately $114,972,126.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David B. Roberts sold 4,123 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $32.14, for a total value of $132,513.22. Following the completion of the sale, the insider now owns 24,482 shares of the company’s stock, valued at $786,851.48. The disclosure for this sale can be found here. Insiders have sold 152,836 shares of company stock valued at $5,415,816 over the last 90 days. Corporate insiders own 23.70% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply